MARKET

PDEX

PDEX

Pro Dex
NASDAQ

Real-time Quotes | Nasdaq Last Sale

36.52
+2.76
+8.18%
After Hours: 36.52 0 0.00% 17:00 10/22 EDT
OPEN
34.00
PREV CLOSE
33.76
HIGH
36.65
LOW
34.00
VOLUME
66.47K
TURNOVER
--
52 WEEK HIGH
36.65
52 WEEK LOW
11.40
MARKET CAP
140.90M
P/E (TTM)
24.33
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
NNDM, CIH, BCLI and CBLI among midday movers
Gainers: Cleveland BioLabs (CBLI) +66%.9F (JFU) +47%.Molecular Data (MKD) +35%.Natuzzi (NTZ) +30%.Aptinyx (APTX) +26%.VOXX International (VOXX) +23%.Pro-Dex (PDEX) +21%.SunLink Health Systems (SSY) +21%.China Index Holdings (CIH) +14%.Anchiano Therapeutics (ANCN) +11%.Losers: Kaixin Auto
Seekingalpha · 2d ago
Pro-Dex: Overvalued At Current Price Unless New Revenue Streams Are Found
Pro-Dex is a manufacturer of surgical tools for the orthopedic, thoracic, and maxocranial facial markets but the company can provide turnkey solutions across numerous industry sectors.After 2 strong quarters and 28% revenue growth in FY20 to $38.3m, Pro-Dex stock currently trades at $29 and PE is 19x.2 new product launches have given Pro-Dex strong growth momentum but it is not clear how this will be sustained.I suspect the share price may correct if the company fails to outperform in Q121 (3m to September '20).If Pro-Dex can realise its potential with new contract wins whilst renewing its contract with its largest customer, I would consider a price
Seekingalpha · 10/09 19:01
When Should You Buy Pro-Dex, Inc. (NASDAQ:PDEX)?
Pro-Dex, Inc. (NASDAQ:PDEX), might not be a large cap stock, but it led the NASDAQCM gainers with a relatively large...
Simply Wall St. · 10/01 16:59
Getting In Cheap On Pro-Dex, Inc. (NASDAQ:PDEX) Is Unlikely
With a median price-to-earnings (or "P/E") ratio of close to 18x in the United States, you could be forgiven for...
Simply Wall St. · 09/08 18:41
Globus Medical Getting Closer To Key Technical Measure
Investor's Business Daily · 09/04 16:08
Stocks With Rising Relative Strength: Zynex
Investor's Business Daily · 09/04 16:01
Insulet Shows Market Leadership With Jump To 82 RS Rating
Investor's Business Daily · 09/01 19:20
Aimmune Therapeutics rallies on Nestle acquiring, Akcea cheers Ionis acquiring 24% remaining stake, ADiTx Therapeutics and Lipocine among major losers
Gainers: Aimmune Therapeutics (AIMT) +172%, Akcea Therapeutics (AKCA) +60%, Pro-Dex (PDEX) +16%, Kindred Biosciences (KIN) +14%, Neuronetics (STIM) +11%.Losers: ADiTx Therapeutics (ADTX) -11%, Lipocine (LPCN) -11%, Orchard Therapeutics (ORTX) -11%, CNS Pharmaceuticals (CNSP) -9%, Anchiano Therapeutics (ANCN) -8%.
Seekingalpha · 08/31 14:58
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PDEX. Analyze the recent business situations of Pro Dex through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PDEX stock price target is 30.00 with a high estimate of 30.00 and a low estimate of 30.00.
EPS
Institutional Holdings
Institutions: 36
Institutional Holdings: 863.03K
% Owned: 22.37%
Shares Outstanding: 3.86M
TypeInstitutionsShares
Increased
6
75.22K
New
11
101.65K
Decreased
6
20.90K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+3.21%
Healthcare Equipment & Supplies
+2.41%
Key Executives
Chairman/Independent Director
Nicholas Swenson
President/Chief Executive Officer/Chief Operating Officer/Director
Richard Van Kirk
Chief Financial Officer
Alisha Charlton
Director
Katrina Philp
Independent Director
Raymond Cabillot
Independent Director
William Farrell
Independent Director
David Hovda
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PDEX
Pro-Dex, Inc. (Pro-Dex) designs and produces surgical and dental instruments and motion control products used in the medical, factory automation and scientific research industries. The Company operates through three segments: Pro-Dex, OMS and Engineering Services Division (ESD). The Pro-Dex segment provides primarily medical and dental instruments using shared production and assembly machines and workforce. The OMS segment is engaged in providing multi-axis motion control applications. In addition to Pro-Dex, the names Micro Motors and Oregon Micro Systems are used for marketing purposes as brand names. The Company provides engineering consulting services, as well as quality and regulatory consulting services, to a range of industries through EDS.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Pro-Dex Inc stock information, including NASDAQ:PDEX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PDEX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PDEX stock methods without spending real money on the virtual paper trading platform.